Proto-Oncogene Proteins p21(ras)

"Proto-Oncogene Proteins p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47.

Descriptor ID	D016283
MeSH Number(s)	D08.811.277.040.330.300.400.500.600 D12.644.360.525.500.600 D12.776.157.325.515.500.600 D12.776.476.525.500.600 D12.776.624.664.700.200
Concept/Terms	Proto-Oncogene Proteins p21(ras) Proto-Oncogene Proteins p21(ras) p21 c-ras c-ras, p21 p21 c ras p21(c-ras) ras Proto-Oncogene Protein p21 ras Proto Oncogene Protein p21 Proto-Oncogene Proteins c-ras Proteins c-ras, Proto-Oncogene Proto Oncogene Proteins c ras c-ras, Proto-Oncogene Proteins Proto-Oncogene Protein ras Proto Oncogene Protein ras ras, Proto-Oncogene Protein ras Proto-Oncogene Product p21 ras Proto Oncogene Product p21 c-ras Proteins c ras Proteins p21(ras) Proto-Oncogene Protein p21(ras) Proto-Oncogene Protein p21(c-N-ras) Proto-Oncogene Protein p21(c-N-ras) p21(N-ras) Proto-Oncogene Protein p21(c-Ha-ras) Proto-Oncogene Protein p21(c-Ha-ras) p21 c-Ha-ras c-Ha-ras, p21 p21 c Ha ras p21(c-Ha-ras) p21 c-H-ras c-H-ras, p21 p21 c H ras c-Ha-ras p21 c Ha ras p21 p21, c-Ha-ras Proto-Oncogene Protein p21(c-Ki-ras) Proto-Oncogene Protein p21(c-Ki-ras) p21 c-Ki-ras c-Ki-ras, p21 p21 c Ki ras p21(c-Ki-ras) p21 c-K-ras c-K-ras, p21 p21 c K ras c-Ki-ras p21 c Ki ras p21 p21, c-Ki-ras

Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins p21(ras)".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Acid Anhydride Hydrolases [D08.811.277.040]
GTP Phosphohydrolases [D08.811.277.040.330]
GTP-Binding Proteins [D08.811.277.040.330.300]
Monomeric GTP-Binding Proteins [D08.811.277.040.330.300.400]
ras Proteins [D08.811.277.040.330.300.400.500]
Proto-Oncogene Proteins p21(ras) [D08.811.277.040.330.300.400.500.600]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intracellular Signaling Peptides and Proteins [D12.644.360]
Monomeric GTP-Binding Proteins [D12.644.360.525]
ras Proteins [D12.644.360.525.500]
Proto-Oncogene Proteins p21(ras) [D12.644.360.525.500.600]
Proteins [D12.776]
Carrier Proteins [D12.776.157]
GTP-Binding Proteins [D12.776.157.325]
Monomeric GTP-Binding Proteins [D12.776.157.325.515]
ras Proteins [D12.776.157.325.515.500]
Proto-Oncogene Proteins p21(ras) [D12.776.157.325.515.500.600]
Intracellular Signaling Peptides and Proteins [D12.776.476]
Monomeric GTP-Binding Proteins [D12.776.476.525]
ras Proteins [D12.776.476.525.500]
Proto-Oncogene Proteins p21(ras) [D12.776.476.525.500.600]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Proto-Oncogene Proteins p21(ras) [D12.776.624.664.700.200]

Below are MeSH descriptors whose meaning is related to "Proto-Oncogene Proteins p21(ras)".

Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins p21(ras)".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Proto-Oncogene Proteins p21(ras)" by people in this website by year, and whether "Proto-Oncogene Proteins p21(ras)" was a major or minor topic of these publications.

Bar chart showing 46 publications over 22 distinct years, with a maximum of 5 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
2000	1	0	1
2001	0	1	1
2003	1	1	2
2005	1	0	1
2008	0	1	1
2009	0	1	1
2010	0	3	3
2011	1	1	2
2012	1	2	3
2013	0	1	1
2014	0	3	3
2015	1	3	4
2016	2	0	2
2017	0	2	2
2019	3	2	5
2020	2	0	2
2021	2	0	2
2022	0	1	1
2023	1	2	3
2024	4	0	4
2025	0	1	1

Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.

Matejcic M, Teer JK, Hoehn HJ, Diaz DB, Shankar K, Gong J, Nguyen NT, Loro?a NC, Coppola D, Fulmer CG, Saglam O, Jiang K, Cress WD, Mu?oz-Antonia T, Flores I, Gordi?n ER, Oliveras Torres JA, Felder SI, Sanchez J, Fleming JB, Siegel EM, Freedman JA, Dutil J, Stern MC, Fridley BL, Figueiredo JC, Schmit SL. Colorectal Tumors in Diverse Patient Populations Feature a Spectrum of Somatic Mutational Profiles. Cancer Res. 2025 May 15; 85(10):1928-1944.

View in: PubMed
Gregory MD, Ofosu-Asante K, Lazarte JMS, Puente PE, Tawfeeq N, Belony N, Huang Y, Offringa IA, Lamango NS. Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis. PLoS One. 2024; 19(10):e0312563.

View in: PubMed
Pandey D, Chauhan SC, Kashyap VK, Roy KK. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers. Eur J Med Chem. 2024 Nov 05; 277:116771.

View in: PubMed
Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, J?nne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov. 2024 Jun 03; 14(6):982-993.

View in: PubMed
Liou GY, Byrd CJ, Storz P, Messex JK. Cytokine CCL9 Mediates Oncogenic KRAS-Induced Pancreatic Acinar-to-Ductal Metaplasia by Promoting Reactive Oxygen Species and Metalloproteinases. Int J Mol Sci. 2024 Apr 26; 25(9).

View in: PubMed
Zhang R, Peng X, Du JX, Boohaker R, Estevao IL, Grajeda BI, Cox MB, Almeida IC, Lu W. Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic Tumorigenesis. Cancer Res. 2023 11 15; 83(22):3739-3752.

View in: PubMed
Montes-Rodr?guez IM, Centeno-Girona H, Rivera-Lynch C, Rivera N, Cruz-Correa M. Molecular profiling of colorectal cancer in a genetically admixed Hispanic population. Cancer Med. 2023 05; 12(10):11686-11702.

View in: PubMed
Perez-Mayoral J, Gonzalez-Pons M, Centeno-Girona H, Montes-Rodr?guez IM, Soto-Salgado M, Su?rez B, Rodr?guez N, Col?n G, Sevilla J, Jorge D, Llor X, Xicola RM, Toro DH, Tous-L?pez L, Torres-Torres M, Reyes JS, L?pez-Acevedo N, Goel A, Rodr?guez-Quilichini S, Cruz-Correa M. Molecular and Sociodemographic Colorectal Cancer Disparities in Latinos Living in Puerto Rico. Genes (Basel). 2023 04 11; 14(4).

View in: PubMed
Ramakrishnan G, Parajuli P, Singh P, Friend C, Hurwitz E, Prunier C, Razzaque MS, Xu K, Atfi A. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. Cell Rep. 2022 11 08; 41(6):111623.

View in: PubMed
Fanini F, Bandini E, Plousiou M, Carloni S, Wise P, Neviani P, Murtadha M, Foca F, Fabbri F, Vannini I, Fabbri M. MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer. Int J Mol Sci. 2021 Dec 12; 22(24).

View in: PubMed

People

Explore

Similar Concepts

Top Journals